IQ-AI, Ltd.

IQ-AI, Ltd.

  • News & Announcements
  • Shareholder Information
  • Investor Relations
  • Significant Shareholders
  • Publications
  • Home
  • Corporate News & Announcements
  • IQ-AI News & Announcements
  • Reduced Gadolinium Approach Validated’
 

BLOG

IQ-AI
Friday, 08 September 2023 / Published in IQ-AI News & Announcements

Reduced Gadolinium Approach Validated’

/**/
RNS Number : 7871L
IQ-AI Limited
08 September 2023
 

8 September 2023

IQ-AI Ltd

(“IQ-AI” or the “Company”)

 

Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR Scanners

 

Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the results of a study that validates IB Neuro’s processing of reduced-dose gadolinium-based contrast agent (GBCA) perfusion studies on 1.5T scanners.

 

The multi-center study, led by Dr. Mark Shiroishi, MD, Assistant Professor of Neuroradiology and Director of Neuro-Oncology Imaging at the Keck School of Medicine of USC, is an extension of the foundational study published in April 2019 (Moving Towards a Consensus DSC-MRI Protocol:  Validation of A Low Flip Angle Single Dose Option as a Reference Standard for Brain Tumors) that validated the  use of a low-dose protocol for acquiring MRI perfusion data. In the 2019 study, it was shown that 3T MRI data collected with 50% less GBCA could provide perfusion maps comparable to the higher dose standard when processed using IB Neuro.

 

IB Neuro has now been validated using this approach on 1.5T scanners.

 

Dynamic susceptibility contrast (DSC) MRI is the most common approach used to measure brain tumor perfusion. Relative cerebral blood volume (rCBV) is the most widely generated parameter map that provides important information regarding tumor grade, prognosis, and treatment response. IB Neuro automatically processes DSC data using its unique contrast leakage (of GBCA) correction technology. It is the only platform that generates quantitative output that can be directly compared across timepoints. This study also makes IB Neuro the only platform proven to provide accurate perfusion maps under low-dose conditions at both 1.5T and 3T MR scanners.

 

“IQ-AI and our collaborators around the world continue to make advancements towards reducing GBCA consumption,” said Trevor Brown, CEO of IQ-AI. “While our patented artificial intelligence technology available in IB Zero G remains in active development, this study provides an immediate option for cutting GBCA by 50% on 1.5T and 3T scanners”, Brown added.

 

“The study demonstrates that a single dose (no preload), low flip angle method does not compromise image quality,” said Dr. Mark Shiroishi, MD. “This is a great added benefit for patients who may have concerns about GBCA risks, and for administrators looking for opportunities to curtail operational expenses”.

 

–ENDS–

 

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

IQ-AI Ltd
Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda
Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797

 

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF) and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Article source
  • Tweet

What you can read next

Result of AGM
Imaging Biometrics Partners with AI Metrics
IMAGING BIOMETRICS, UNIVERSITY OF PENNSYLVANIA ENTER LICENSE AGREEMENT

Recent Posts

  • IQ-AI shares cease trading on the OTCQB

    /**/ RNS Number : 9599M IQ-AI Limited 19 Septem...
  • Update on Collaboration Agreement with Mayo Clinic

    /**/ RNS Number : 8096J IQ-AI Limited 18 August...
  • IB & GE HealthCare Enter into Commercial Agreement

    /**/ RNS Number : 8077J IQ-AI Limited 18 August...
  • Half-year Report

    /**/ RNS Number : 5460J IQ-AI Limited 17 August...
  • Orphan Drug Designation for GaM in Pediatric GBM

    /**/ RNS Number : 8411F IQ-AI Limited 13 July 2...
  • Policies
  • Investor Information

iq-ai@imagingbiometrics.com

P. O. Box 264
Forum 4, Grenville Street
St Helier, Jersey, Channel Islands
JE4 8TQ

Copyright © 2015-2023 IQ-AI. All Rights Reserved
TOP
Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT